Clinical Research Trials Division
The Clinical Research Trials Division oversees and develops strategy for all Foundation activities relating to the development and promotion of clinical research trials. Specific responsibilities include identifying strategic areas/initiatives influencing interventional radiologists' participation in clinical research trials and promoting the importance of clinical research.
SIR Foundation offers site selection services for multi-center clinical research trials. Please call the SIR Foundation at (703) 681-1805 for details.
Funding Source Development Grant
• Example of a Letter of Intent
IR Clinical Trials Searchable Database
SIR Foundation has identified renal ablation as the spring 2010 Research Consensus Panel (RCP) topic. The Lead Investigator of this RCP will be Dr. Christos Georgiades, M.D., Ph.D. The RCP will be held Monday, April 26, 2010 in Northern Virginia.
Current IR Research Studies of Interest
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis (ATTRACT) In June 2008, the NHLBI announced that it would provide funding for Dr. Suresh Vedantham's ATTRACT trial for five years. Dr. Vedantham developed the Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-directed Thrombolysis (ATTRACT) trial in response to the recommendation of the 2004 research consensus panel on endovascular venous thromboembolism (VTE) interventions. The SIR Foundation continues to work as a collaborating institution with Dr. Vedantham and his team at Washington University.
Pulmonary Embolism Response to Fragmentation, Embolectomy and Catheter Thrombolysis (PERFECT) registry. SIR member William T. Kuo, MD, Stanford University, Palo Alto, Calif., is principal investigator for the Pulmonary Embolism Response to Fragmentation, Embolectomy and Catheter Thrombolysis (PERFECT) registry. The primary objective of this study is to capture high-quality patient safety and effectiveness data on catheter-directed thrombolysis (CDT) for acute pulmonary embolism (PE). The goal will be achieved by capturing a concise set of immediate and short-term functional and clinical outcome data for PE patients undergoing CDT. Secondary study objectives include assessing and benchmarking clinical practice patterns (patient selection, optimal technique, use of procedure worldwide). These objectives will be achieved through the capture of selected process data for patients included in the registry. Data collected in this study may also be used to develop and refine standards of care for use of CDT for PE and to facilitate the design of further clinical trials.
He would like SIR members to contact him if they are interested in participating in this multicenter study. The official trial listing can be found here.
A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion. Interventional Radiologists, Jeff Geschwind, MD and Michael Soulen, MD (Co-Chairs) are part of a study team lead by Dr. John Kauh, MD (Study Chair) implementing this phase III, randomized, double-blind trial. This is an Eastern Cooperative Oncology Group (ECOG) clinical trial, endorsed by CTEP/NCI. It is open to all the cooperative groups. For a brief description please read this summary.
The Role of Hypoxia in Venous Neointimal Hyperplasia in Hemodialysis Grafts. SIR Foundation Pilot Research Grants provided Dr. Sanjay Misra with the seed funding he needed to achieve this $2 million dollar grant from The National Heart Lung and Blood Institute (NHLBI). Dr. Misra is an Associate Professor of Radiology at the Mayo Clinic School of Medicine in Rochester, MN. His IR research focus is understanding the mechanisms of hemodialysis graft failure. Beginning about ten years ago, he was awarded SIR Foundation Pilot grants and was then able to obtain funding from The American Heart Association. He authored over a dozen original publications about his research.